Crossmark

Continuous renal replacement therapy versus intermittent hemodialysis as first modality for renal replacement therapy in severe acute kidney injury: a secondary analysis of AKIKI and IDEAL-ICU studies

Crossref DOI link: https://doi.org/10.1186/s13054-022-03955-9

Published Online: 2022-04-04

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gaudry, Stéphane

Grolleau, François

Barbar, Saber

Martin-Lefevre, Laurent

Pons, Bertrand

Boulet, Éric

Boyer, Alexandre

Chevrel, Guillaume

Montini, Florent

Bohe, Julien

Badie, Julio

Rigaud, Jean-Philippe

Vinsonneau, Christophe

Porcher, Raphaël

Quenot, Jean-Pierre

Dreyfuss, Didier
Funding

Funding for this research was provided by:

Ministry of health, France (AOM12456, A00519-34)
License Information

Text and Data Mining valid from 2022-04-04

Version of Record valid from 2022-04-04
More Information

Article History

Received: 10 February 2022

Accepted: 3 March 2022

First Online: 4 April 2022

Declarations

:

: The AKIKI trial and the IDEAL-ICU trial received approval for all participating centers from competent French legal authority (Comité de Protection des Personnes d’Ile de France VI, ID RCB 2013-A00765-40, NCT01932190 for AKIKI and Comité de Protection des Personnes Est I ID RCB 2012-A00519-34 for IDEAL-ICU), and consent of patient or relatives was obtained before inclusion (except in emergencies where deferred consent was allowed by the Institutional Review Board).

: Patients or their surrogates were informed both verbally and with a written document by the investigators. They could refuse to participate at any time, and their decision was recorded in patient files.

: None of the authors have competing interests in the manuscript.

Document is current

Any future updates will be listed below